เกี่ยวกับตอนนี้
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with Peter Kolchinsky, PhD, Founder and Managing Partner of RA Capital Management, to discuss if the U.S. market-based approach to pricing novel prescription medicines could result in paying more than they are worth and if companies and company builders should use health economic modeling to support their value propositions.
ภาษาอังกฤษ
สหรัฐอเมริกา
สำเนาบทสนทนา 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
ค้นหาตอนที่ผ่านมา
ค้นหาตอนที่ผ่านมาของ Perspectives by the Leerink Center for Pharmacoeconomics
ตอนอื่นๆ ใน PODCAST นี้
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, interviews James Chambers, PhD, MPharm, Professor of Medicine in the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, to dig into specialty drug coverage and what it might look like in 2026.
Diane Vieira, Head of Marketing & Communications at Leerink Partners, interviews Melanie Whittington, PhD, Head of the Leerink Center of Pharmacoeconomics (CPE), to discuss the one-year anniversary of CPE and everything they thought they knew but actually didn’t.
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech, to discuss the impact of the Inflation Reduction Act on cancer drug development and a middle ground between a market-based approach and a government-b…
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with John M. O'Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council & Former Trump Drug Pricing Advisor, to tackle some big questions like if it is possible to reward innovation without bus…
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Vivek Subbiah, MD, David Hong, MD, and Steve Potts, PhD, MBA to discuss if pan-tumor approval strategies offer a path forward for broader, faster adoption across larger patient populations. Given the slow adoption cur…
ข้อสงวนสิทธิ์: พอดแคสต์และอาร์ตเวิร์คที่ฝังอยู่ในหน้านี้มาจาก The Leerink Center for Pharmacoeconomics ซึ่งเป็นทรัพย์สินของเจ้าของและไม่มีส่วนเกี่ยวข้องหรือรับรองโดย Listen Notes, Inc.
